Comparison of the sedative effect of remimazolam compounded with etomidate in combination with oliceridine or sufentanil for gastroenteroscopy: a single-center, randomized controlled clinical trial

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2400082452

Enrollment

Unknown

Registered

2024-03-29

Start date

2024-04-01

Completion date

Unknown

Last updated

2024-04-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

General anesthesia without intubation

Interventions

RE-Oliceridine Group:remimazolam compounded with etomidate in combination with oliceridine

RE-Sufentanil Group:remimazolam compounded with etomidate in combination with sufentanil

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) age =18 years, elective gastroscopy and colonoscopy under procedural sedation; (2) ASA I-III.

Exclusion criteria

Exclusion criteria: (1) refusal to sign informed consent; (2) severe respiratory depression; (3) acute or severe bronchial asthma; (4) known or suspected gastrointestinal obstruction; (5) known allergy to the medications and ingredients used in this study; (6) severe hepatic, renal, and adrenal insufficiency; (7) chronic opioid use; (8) electrocardiographic examination suggestive of abnormal QT intervals; (9) chronic use of benzodiazepine drugs; (10) anticipated difficult airway.

Design outcomes

Primary

Measure	Time frame
respiratory depression;	—

Secondary

Measure	Time frame
hypoxemia;Airway interventions;Sedation/anesthesia success rate;	—

Countries

China

Contacts

Public ContactShoushi Wang

Qingdao Central Hospital

wangshoushi1226@126.com+86 185 6185 6159

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026